Showing results (191-200 of 201) with videos related to

Sort By:
Pageof 21
The Journal of Biological Chemistry|February 22, 2021
Mutational and biophysical robustness in a prestabilized monobodyPeter G Chandler, Li Lynn Tan, Benjamin T Porebski, et al.
Acta Crystallographica. Section D, Biological Crystallography|September 27, 2006
Automation of sample mounting for macromolecular crystallographyF Cipriani, F Felisaz, L Launer, et al.
Acta Crystallographica. Section D, Biological Crystallography|September 27, 2006
First steps towards effective methods in exploiting high-throughput technologies for the determination of human protein structures of high biomedical valueL Banci, I Bertini, S Cusack, et al.
Molecular Pharmaceutics|August 27, 2021
Preclinical Evaluation of a Fluorescent Probe Targeting Receptor CDCP1 for Identification of Ovarian CancerYaowu He, Tashbib Khan, Thomas Kryza, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Acta Crystallographica. Section D, Biological Crystallography|September 27, 2006
High-throughput sample handling and data collection at synchrotrons: embedding the ESRF into the high-throughput gene-to-structure pipelineA Beteva, F Cipriani, S Cusack, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
Nature Structural & Molecular Biology|July 8, 2025
A nanobody-based therapeutic targeting Nipah virus limits viral escapeAriel Isaacs, Guillermo Valenzuela Nieto, Xinghai Zhang, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Molecular Psychiatry|November 1, 2022
SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia through spike proteinEduardo A Albornoz, Alberto A Amarilla, Naphak Modhiran, et al.
Pageof 21